Anti-Hu CD14 APC-Cy1537

Anti-Hu CD14 APC-Cy1537

• CAS Number: 9007-83-4
• Clone: MEM-15
• Format: APC-Cy1537
• Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
• References & Citations: *Majer F, Vlaskova H, Krol L, Kalina T, Kubanek M, Stolnaya L, Dvorakova L, Elleder M, Sikora J: Danon disease: a focus on processing of the novel LAMP2 mutation and comments on the beneficial use of peripheral white blood cells in the diagnosis of LAMP2 deficiency. Gene. 2012 May 1498(2):183-95., URL: https://pubmed.ncbi.nlm.nih.gov/22365987/,*Kanderova V, Kuzilkova D, Stuchly J, Vaskova M, Brdicka T, Fiser K, Hrusak O, Lund-Johansen F, Kalina T: High-resolution Antibody Array Analysis of Childhood Acute Leukemia Cells. Mol Cell Proteomics. 2016 Apr15(4):1246-61., URL: http://www.ncbi.nlm.nih.gov/pubmed/26785729 ,*Jeraiby M, Sidi Yahya K, Depince-Berger AE, Lambert C: Microbicidal activity measured by flow cytometry: Optimization and standardization for detection of primary and functional deficiencies. J Immunol Methods. 2016 Sep 29. pii: S0022-1759(16)30220-4., URL: https://www.ncbi.nlm.nih.gov/pubmed/27693641 ,*Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, Aepfelbacher M, Heesemann J: Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med. 2002 Oct 21196(8):1017-24., URL: http://www.ncbi.nlm.nih.gov/pubmed/12391013 ,*Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT: Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma treatment of normal human subjects. Blood. 1997 Oct 1590(8):3187-94., URL: http://www.ncbi.nlm.nih.gov/pubmed/9376602 ,*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997)., URL: ,*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995)., URL: ,*Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989)., URL: ,*Leukocyte Typing III., McMichael A. J. et al (Eds.), Oxford University Press (1987)., URL: ,*Bazil V, Horejsi V, Baudys M, Kristofova H, Strominger JL, Kostka W, Hilgert I: Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen. Eur J Immunol. 1986 Dec16(12):1583-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/3493149?dopt=A,*Funda DP, Tucková L, Farré MA, Iwase T, Moro I, Tlaskalová-Hogenová H: CD14 is expressed and released as soluble CD14 by human intestinal epithelial cells in vitro: lipopolysaccharide activation of epithelial cells revisited. Infect Immun. 2001 Jun69(6):3772-81., URL: http://www.ncbi.nlm.nih.gov/pubmed/11349042 ,*Cejkova P, Nemeckova I, Broz J, Cerna M: TLR2 and TLR4 expression on CD14++ and CD14+ monocyte subtypes in adult-onset autoimmune diabetes. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 May 4. doi: 10.5507/bp.2015.016., URL: http://www.ncbi.nlm.nih.gov/pubmed/?term=cejkova+p+nemeckova+i+broz+j+cerna+m ,
• Other References: *Juan TS, Hailman E, Kelley MJ, Wright SD, Lichenstein HS: Identification of a domain in soluble CD14 essential for lipopolysaccharide (LPS) signaling but not LPS binding. J Biol Chem. 1995 Jul 21270(29):17237-42., URL: https://pubmed.ncbi.nlm.nih.gov/7542233/,*Lodrup Carlsen KC, Granum B: Soluble CD14: role in atopic disease and recurrent infections, including otitis media. Curr Allergy Asthma Rep. 2007 Nov7(6):436-43., URL: https://pubmed.ncbi.nlm.nih.gov/17986374/,*Asai Y, Makimura Y, Kawabata A, Ogawa T: Soluble CD14 discriminates slight structural differences between lipid as that lead to distinct host cell activation. J Immunol. 2007 Dec 1179(11):7674-83., URL: https://pubmed.ncbi.nlm.nih.gov/18025213/,*Fernández-Real JM, Broch M, Richart C, Vendrell J, López-Bermejo A, Ricart W: CD14 monocyte receptor, involved in the inflammatory cascade, and insulin sensitivity. J Clin Endocrinol Metab. 2003 Apr88(4):1780-4., URL: https://pubmed.ncbi.nlm.nih.gov/12679473/,